This article is more than 5 years old. Information may no longer be current.

OptiMedica receives $16 million in Series C funding

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SANTA CLARA, Calif. — OptiMedica has secured $16 million in Series C financing from existing investment partners Kleiner, Perkins, Caufield & Byers and Alloy Ventures, as well as new investment partner DAG Ventures, the company announced in a press release.

The company plans to use the financing to expand its market presence and to develop its new technology portfolio, the release said.

OptiMedica owns exclusive global rights to the PASCAL photocoagulator system.